Latest Regulatory Milestones News

The Australian Competition and Consumer Commission has signaled no opposition to DP World Australia’s acquisition of Silk Logistics, advancing the deal but leaving key approvals pending.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Medallion Metals has taken a crucial step by acquiring 258 hectares near Ravensthorpe to meet environmental offset requirements, advancing its gold project approvals under federal law.

MRG Metals has achieved a pivotal milestone with the granting of the Corridor South 11137 Mining Licence in Mozambique, setting the stage for production within 12 to 18 months under its fully funded Corridor Sands Project.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Jindalee Lithium has appointed Ian Rodger as Managing Director, marking a leadership milestone as the company advances its McDermitt Lithium Project. Rodger’s promotion follows his pivotal role in delivering key project studies and securing regulatory milestones.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

Alkane Resources has secured key regulatory approvals from FIRB and ASIC, paving the way for its planned merger with Mandalay Resources. This milestone brings the companies closer to creating a diversified Australian gold and antimony producer.